Figure 3
ADA specific activity and substrate levels after neonatal BMT. ADA enzyme specific activity (nmol of adenosine converted to inosine/min/mg protein) was determined in tissue lysates.12 Age-matched, Ada+/+ congenic controls were compared at day 16 (n = 4) and day 60 (n = 2) to untreated Ada−/− mice (n = 3) and Ada−/− treated with neonatal BMT at day 16 (n = 3) and day 60 (n = 6) and to Ada−/− mice receiving ERT with PEG-ADA at day 16 (n = 2) and at day 60 (n = 2). ADA specific activity in the thymus (A), spleen (B), lung (C), and liver (D). ADA substrate concentrations (nmol/mg protein) of adenosine and deoxyadenosine in thymus (E), spleen (F), lung (G), and liver (H).

ADA specific activity and substrate levels after neonatal BMT. ADA enzyme specific activity (nmol of adenosine converted to inosine/min/mg protein) was determined in tissue lysates.12  Age-matched, Ada+/+ congenic controls were compared at day 16 (n = 4) and day 60 (n = 2) to untreated Ada−/− mice (n = 3) and Ada−/− treated with neonatal BMT at day 16 (n = 3) and day 60 (n = 6) and to Ada−/− mice receiving ERT with PEG-ADA at day 16 (n = 2) and at day 60 (n = 2). ADA specific activity in the thymus (A), spleen (B), lung (C), and liver (D). ADA substrate concentrations (nmol/mg protein) of adenosine and deoxyadenosine in thymus (E), spleen (F), lung (G), and liver (H).

Close Modal

or Create an Account

Close Modal
Close Modal